Fortem Financial Group, LLC Incyte Corp Transaction History

Fortem Financial Group, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 25, 2022	SELL	$66.18 - $83.18 $741,282 - $931,699	-11,201 Reduced 33.68%	22,054 $1.68 Million
Q1 2022 Apr 27, 2022	BUY	$66.02 - $79.71 $1.42 Million - $1.72 Million	21,531 Added 183.65%	33,255 $2.64 Million
Q4 2021 Jan 20, 2022	SELL	$63.34 - $74.11 $628,079 - $734,874	-9,916 Reduced 45.82%	11,724 $861,000
Q3 2021 Oct 15, 2021	BUY	$68.67 - $84.02 $42,712 - $52,260	622 Added 2.96%	21,640 $1.49 Million
Q2 2021 Jul 14, 2021	BUY	$79.87 - $87.53 $1.68 Million - $1.84 Million	21,018 New	21,018 $1.77 Million

644

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16.6B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Fortem Financial Group, LLC, based on Form 13F filings with the SEC.

Stay updated on Fortem Financial Group, LLC with notifications on news.